Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak.
The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.
['de la Cruz-Benito|Beatriz|B|0000-0002-3223-0121', 'Lázaro-Del Campo|Paula|P|0000-0001-9089-4789', 'Ramírez-López|Andrés|A|', 'de Soto-Álvarez|Teresa|T|', 'Sánchez-Vadillo|Irene|I|', 'García-Pérez|Eduardo|E|', 'Dos Santos-Ortas|Abel|A|', 'Humala-Barbier|Karem|K|', 'López-de la Guía|Ana|A|', 'Casado-Abad|Gema|G|', 'Jiménez-Yuste|Victor|V|', 'Canales-Albendea|Miguel|M|0000-0002-6550-2621']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D000900:Anti-Bacterial Agents D000971:Antineoplastic Combined Chemotherapy Protocols D000998:Antiviral Agents D017963:Azithromycin D001424:Bacterial Infections D000086382:COVID-19 D000086742:COVID-19 Testing D003520:Cyclophosphamide D004317:Doxorubicin D064147:Febrile Neutropenia D005260:Female D016179:Granulocyte Colony-Stimulating Factor D006801:Humans D006886:Hydroxychloroquine D017053:Infection Control D016403:Lymphoma, Large B-Cell, Diffuse D008297:Male D008875:Middle Aged D058873:Pandemics D000069293:Plasmablastic Lymphoma D011241:Prednisone D000069283:Rituximab D000086402:SARS-CoV-2 D013030:Spain D015163:Superinfection D014750:Vincristine
B cell lymphoma high-grade COVID-19 SARS-CoV-2 haematological malignancies